Latest & greatest articles for hydroxychloroquine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydroxychloroquine

1. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. Full Text available with Trip Pro

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation (...) to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376

2020 NEJM

2. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Full Text available with Trip Pro

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada (...) testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6

2020 NEJM

3. COVID-19: Treatment with Hydroxychloroquine (HCQ)

COVID-19: Treatment with Hydroxychloroquine (HCQ) COVID-19: TREATMENT WITH HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated May 18, 2020 3:00 pm All links rechecked May 17 unless otherwise noted. This Rapid Guidance Summary is a description of existing guidance and evidence reviews from a variety of sources that was in effect at the time of publication. It should not be used or interpreted as a clinical practice guideline (...) , but instead can be used in development of local recommendations and policies. Key questions answered in this summary • Is hydroxychloroquine safe and effective for treatment of COVID-19 disease? Use of hydroxychloroquine for prevention of COVID-19 disease is outside the scope of this report. Summary of major recommendations • Use of hydroxychloroquine and chloroquine for treatment of COVID-19 disease is considered an off-label indication. Clinical trials are in progress. • Current clinical evidence

2020 Centre for Evidence-Based Practice, Penn Medicine

4. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 Full Text available with Trip Pro

A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Acad Emerg Med Actions . 2020 Jun;27(6):493-504. doi: 10.1111/acem.14005. Epub 2020 May 29. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19 , , Affiliations Expand Affiliations 1 From the, SUNY Downstate Medical Center, Brooklyn, NY. 2 Department of Emergency Medicine, SUNY Downstate Medical Center, Brooklyn, NY. PMID: 32359203 PMCID: DOI

2020 EvidenceUpdates

5. Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis Full Text available with Trip Pro

Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis "Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-Analysis." - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show (...) Permalink Copy Page navigation Diabetes Metab Syndr Actions . 2020 May 12;14(4):589-596. doi: 10.1016/j.dsx.2020.05.017. Online ahead of print. "Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-Analysis." , , , Affiliations Expand Affiliations 1 Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, West Bengal, India. Electronic address: draksingh_2001@yahoo.com. 2 College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India. 3 Gynaecology

2020 EvidenceUpdates

6. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) Full Text available with Trip Pro

An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Clin Drug Investig Actions . 2020 Jul;40(7):591-601. doi: 10.1007/s40261-020-00927-1. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19) , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605 006, India. 2 Department of Pharmacology, KPC

2020 EvidenceUpdates

7. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. (Abstract)

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Hydroxychloroquine and chloroquine have antiviral effects in vitro against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19).PubMed (via MEDLINE), EMBASE (via Ovid), Scopus, Web of Science, Cochrane Library, bioRxiv (...) , Preprints, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and the Chinese Clinical Trials Registry from 1 December 2019 until 8 May 2020.Studies in any language reporting efficacy or safety outcomes from hydroxychloroquine or chloroquine use in any setting in adults or children with suspected COVID-19 or at risk for SARS-CoV-2 infection.Independent, dually performed data extraction and quality assessments.Four randomized controlled trials, 10 cohort

2020 Annals of Internal Medicine

8. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Full Text available with Trip Pro

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated (...) in COVID-19.We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine

2020 Lancet

9. Web Exclusive. Annals Consult Guys - Hydroxychloroquine: Update on an Old Drug. (Abstract)

Web Exclusive. Annals Consult Guys - Hydroxychloroquine: Update on an Old Drug. [Figure: see text].

2020 Annals of Internal Medicine

10. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. Full Text available with Trip Pro

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.Comparative observational study using data collected from routine care.Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March (...) 2020.181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care.Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group).The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress

2020 BMJ

11. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Full Text available with Trip Pro

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).Multicentre, open label, randomised controlled trial.16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.150 patients admitted to hospital with laboratory confirmed covid-19 (...) were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).Hydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).Negative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according

2020 BMJ

12. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Full Text available with Trip Pro

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events.To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital (...) follow-up was April 24, 2020.Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither.Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation).Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either

2020 JAMA

13. COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine

COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website COVID-19 Clinical Trials Report Card: Chloroquine and Hydroxychloroquine May 11, 2020 Nicholas J. DeVito, Michael Liu, Jeffrey K Aronson On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence (...) -Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford Correspondence to Chloroquine and hydroxychloroquine (CQ/HCQ) are antimalarial medications and are also used in the treatment of lupus erythematosus and rheumatoid arthritis. Both have been prominently touted as prospective candidates for the treatment and/or prevention of infection by SARS-Cov-2. This has led to an explosion of research into these treatments. Here we assess the trial designs specified

2020 Oxford COVID-19 Evidence Service

14. Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Full Text available with Trip Pro

Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Prescrire IN ENGLISH - Spotlight ''New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands)'', 16 April 2020 {1} {1} {1} | | > > > New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other (...) brands) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands) NEWS UPDATE As of mid-April 2020, more and more clinical data are confirming that the combination of hydroxychloroquine (Plaquenil°) with azithromycin

2020 Prescrire

15. Covid-19 and hydroxychloroquine (Plaquenil): new data show no evidence of efficacy Full Text available with Trip Pro

Covid-19 and hydroxychloroquine (Plaquenil): new data show no evidence of efficacy Prescrire IN ENGLISH - Spotlight ''Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy'', 16 April 2020 {1} {1} {1} | | > > > Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |    (...) |   |  Spotlight Covid-19 and hydroxychloroquine (Plaquenil°): new data show no evidence of efficacy NEWS UPDATE The results of a new randomised comparative but non-blinded trial of high-dose hydroxychloroquine (Plaquenil°) versus standard care in 150 patients hospitalised for covid-19 have been published. The only notable difference between the groups was the high incidence of adverse effects in the group treated with hydroxychloroquine. The results of other studies (non-randomised

2020 Prescrire

16. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19

Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology ') Search All Types Search or Menu and use of hydroxychloroquine and chloroquine in clinical practice are outlined below. Hydroxychloroquine or chloroquine therapy should occur in the context of a clinical trial or registry, until sufficient evidence is available for use in clinical (...) practice. Hydroxychloroquine or chloroquine use outside of a clinical trial should occur at the direction of an infectious disease or COVID-19 expert, with cardiology input regarding QT monitoring. with detailed and general arrhythmia monitoring considerations are also available. The intensity of QT and arrhythmia monitoring should be considered in the context of potential drug benefit, drug safety, resource availability and quarantine considerations. IRB-approved protocols should guide use

2020 American College of Cardiology

17. Hydroxychloroquine with or without azithromycin for COVID-19

Hydroxychloroquine with or without azithromycin for COVID-19 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca March 30 (...) , 2020 COVID-19 Rapid Reviews Along with regular Tools for Practice, the PEER team will be writing rapid reviews to address COVID-19 topics relevant for primary care. The evidence is changing rapidly and it is possible that as you read this, new evidence will already be available. We will try our best to stay in front and keep you up-to- date during these challenging times. Hydrochloroquine with or without azithromycin for COVID-19 Clinical Question: Is hydroxychloroquine (with or without

2020 Tools for Practice

18. Covid-19 and hydroxychloroquine: caution

Covid-19 and hydroxychloroquine: caution Prescrire IN ENGLISH - Spotlight ''Covid-19 and hydroxychloroquine: caution '', 30 March 2020 {1} {1} {1} | | > > > Covid-19 and hydroxychloroquine: caution Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Covid-19 and hydroxychloroquine: caution NEWS UPDATE Hydroxychloroquine was not shown to be effective (...) in a randomised trial in 30 patients with covid-19, the results of which were published in China in early March 2020. The hypothesis that this drug sometimes worsens covid-19 has not been ruled out. Short-course treatment with hydroxychloroquine carries a risk of various adverse effects, some of which can be fatal, especially in the event of an overdose. As of 23 March 2020, we were unable to identify any published results of randomised trials of hydroxychloroquine in patients with SARS-CoV-2 infection, i.e

2020 Prescrire

19. Covid-19 and hydroxychloroquine: uncertainties and unanswered questions

Covid-19 and hydroxychloroquine: uncertainties and unanswered questions Prescrire IN ENGLISH - Spotlight ''Covid-19 and hydroxychloroquine: uncertainties and unanswered questions '', 02 April 2020 {1} {1} {1} | | > > > Covid-19 and hydroxychloroquine: uncertainties and unanswered questions Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Covid-19 (...) and hydroxychloroquine: uncertainties and unanswered questions NEWS UPDATE Results of a comparative trial of hydroxychloroquine (Plaquenil°) in 62 patients were published at the end of March 2020. The remaining uncertainty in the wake of these results means that the comparative trials currently underway must be continued, and great care should still be taken in the use of hydroxychloroquine, given its cardiac and other harms. Results of a Chinese comparative trial of hydroxychloroquine (Plaquenil°) were published

2020 Prescrire

20. Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine

Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine Guiding Principles from the American College of Rheumatology for Scarce Resource Allocation During the COVID-19 Pandemic: The Case of Hydroxychloroquine Background Ethical principles must be balanced when making decisions about scarce resource allocation. In extreme circumstances, like the COVID-19 pandemic caused by the SARS-CoV-2 virus (...) , the focus of medical care “shifts from the needs of the individual (ethical principle of autonomy) to the needs of the community as a whole (ethical principle of distributive justice)” (1) with the goal of achieving the greatest good for the greatest number of people. Hydroxychloroquine (HCQ) is an essential medicine for patients with systemic lupus erythematosus (SLE). It is also a mainstay of therapy for many patients with rheumatoid arthritis. In the case of SLE, including pregnant women with SLE

2020 American College of Rheumatology